Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced positive Phase III study results for Anlotinib Hydrochloride Capsules combined with Penpulimab Injection in treating advanced hepatocellular carcinoma, presented at ESMO 2024. The study met its predefined endpoints, showing a median progression-free survival of 6.9 months and overall survival of 16.5 months. The company is planning to submit a marketing application for this new treatment indication, expanding Anlotinib’s potential benefits to more cancer patients.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
